Summary
Eli Lilly and Company (LLY) announced significant leadership changes through an 8-K filing on July 27, 2016. The most impactful news for investors is the upcoming retirement of its long-serving President and CEO, John Lechleiter, effective December 31, 2016. Dr. Lechleiter, who has been with the company for 37 years and led as CEO since 2008, will also retire from the board of directors in May 2017. Concurrently, the board has elected David A. Ricks as the new President and CEO, set to take office on January 1, 2017. Mr. Ricks, a seasoned executive within Lilly with extensive experience in commercial operations and a strong understanding of R&D, will also transition to Chairman of the Board in June 2017. This leadership transition marks a new chapter for Lilly, and investors will be keen to observe how Mr. Ricks will steer the company's strategic direction.
Key Highlights
- 1John Lechleiter, President, CEO, and Chairman of the Board, announced his retirement as President and CEO effective December 31, 2016, and as Chairman and Board member effective May 31, 2017.
- 2David A. Ricks has been elected as the new President and CEO, effective January 1, 2017.
- 3Mr. Ricks will also be elected as a director effective January 1, 2017, and as Chairman of the Board effective June 1, 2017.
- 4The Board of Directors has increased its size by one to accommodate Mr. Ricks' appointment as a director.
- 5Mr. Ricks brings extensive experience in Lilly's commercial operations and an understanding of research and development, having held various leadership roles since joining in 1996.
- 6Mr. Ricks' compensation as CEO will include an annualized base salary of $1.4 million and eligibility for an annualized non-equity incentive plan compensation of $2.1 million.
- 7A press release detailing these leadership changes is filed as an exhibit to the 8-K.